WASHINGTON (Reuters) - Eli Lilly and Co made misleading claims about its Cymbalta drug in a promotion to doctors about its use in treating nerve-related pain, U.S. regulators said in a letter released on Tuesday.The promotion “is false or misleading in that it overstates the efficacy of Cymbalta and omits some of the most serious and important risk information associated with its use,” the Food and Drug Administration said in a letter to the company.
